Torii Pharmaceutical Co (TSE:4551) Total Liabilities : 円13,907 Mil (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co Total Liabilities?

Torii Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was 円13,907 Mil.

Torii Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 (円13,587.00 Mil) to Dec. 2023 (円13,300.00 Mil) but then increased from Dec. 2023 (円13,300.00 Mil) to Mar. 2024 (円13,907.00 Mil).

Torii Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (円13,796.00 Mil) to Dec. 2022 (円14,465.00 Mil) but then declined from Dec. 2022 (円14,465.00 Mil) to Dec. 2023 (円13,300.00 Mil).

Torii Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Torii Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torii Pharmaceutical Co Total Liabilities Chart

Torii Pharmaceutical Co Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

26,818.00

10,937.00

13,796.00

14,465.00

13,300.00

Torii Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															12,510.00	13,005.00	13,587.00	13,300.00	13,907.00

Torii Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Torii Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12504	+	(22	+	296
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	478)
	=	13,300

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	133432	-	120132
	=	13,300

Torii Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13181	+	(0	+	301
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	425)
	=	13,907

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	132947	-	119040
	=	13,907

Torii Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines